Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee.
- Author:
Moon Jin KIM
1
;
Young Sam KIM
;
Sung Yong OH
;
Suee LEE
;
Young Jin CHOI
;
Young Mi SEOL
;
Min Jae PARK
;
Ki Hyang KIM
;
Lee Chun PARK
;
Jung Hun KANG
;
In Gyu HWANG
;
Soon Il LEE
;
Seung Taek LIM
;
Hyo Song KIM
;
Ho Yeong LIM
;
Sun Young RHA
;
Hyo Jin KIM
Author Information
- Publication Type:Original Article
- Keywords: Urinary bladder; Adenocarcinoma; Drug therapy
- MeSH: Adenocarcinoma*; Diagnosis; Disease-Free Survival; Drug Therapy*; Female; Follow-Up Studies; Gynecology*; Hematuria; Humans; Recurrence; Retrospective Studies*; Urinary Bladder Neoplasms; Urinary Bladder*
- From:The Korean Journal of Internal Medicine 2018;33(2):383-390
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Because of rarity, role of chemotherapy of bladder adenocarcinoma are still unidentified. Therefore, we performed a retrospective analysis of the clinical features and chemotherapy outcomes of bladder adenocarcinoma. METHODS: Eligible patients for this retrospective analysis were initially diagnosed with bladder adenocarcinoma and presented with a clinically no other primary site of origin. The collected data included age, gender, performance status, stage, hemoglobin, albumin, initial date of diagnosis, treatment modality utilized, response to treatment, presence of relapse, last status of patient, and last date of follow-up. RESULTS: We retrospectively reviewed 29 patients, who were treated with chemotherapy for bladder adenocarcinoma at 10 Korean medical institutions from 2004 to 2014. The median age of patients was 58 years (range, 17 to 78) and 51.7% of the patients were female. Urachal adenocarcinoma was identified in 15 patients. Of 27 symptomatic patients, 22 experienced gross hematuria. Twelve patients were treated with 5-f luorouracil based chemotherapy, five were gemcitabine based, three were taxane and others. Thirteen of them achieved complete response (10.3%) or partial response (34.5%). Median progression-free survival (PFS) and overall survival (OS) for all patients were 10.6 months (95% confidence interval [CI], 9.5 to 11.6) and 24.5 months (95% CI, 1.2 to 47.8), respectively. The cases of urachal adenocarcinoma exhibited worse tendency in PFS and OS (p = 0.024 and p = 0.046, respectively). CONCLUSIONS: Even though bladder adenocarcinoma had been observed moderate effectiveness to chemotherapy, bladder adenocarcinoma is a highly aggressive form of bladder cancer. PFS and OS were short especially in urachal carcinoma.
